Compare ESNT & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESNT | TWST |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.2B |
| IPO Year | 2013 | 2018 |
| Metric | ESNT | TWST |
|---|---|---|
| Price | $69.41 | $115.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $67.29 | $46.88 |
| AVG Volume (30 Days) | 481.3K | ★ 1.5M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | 0.73 | ★ 63.89 |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $1,260,935,000.00 | $376,572,000.00 |
| Revenue This Year | $1.12 | $18.91 |
| Revenue Next Year | $3.37 | $15.07 |
| P/E Ratio | $17.85 | ★ N/A |
| Revenue Growth | 1.45 | ★ 20.32 |
| 52 Week Low | $55.34 | $23.30 |
| 52 Week High | $70.00 | $126.40 |
| Indicator | ESNT | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 58.20 |
| Support Level | $63.90 | $84.39 |
| Resistance Level | $70.00 | N/A |
| Average True Range (ATR) | 1.63 | 8.24 |
| MACD | 0.13 | 0.99 |
| Stochastic Oscillator | 85.37 | 77.53 |
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.